You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Litigation Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

✉ Email this page to a colleague

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

Docket	⤷ Sign Up	Date Filed	2019-10-17
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
2022-05-19			Zydus infringement trial concerning U.S. Patent Nos. 8,101,659, 8,796,331, 8,877,938 and 9,388,134 to May… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-10-17	1	Complaint	expiration of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), 8,877,938 (… (the “’938 patent”), and/or 9,388,134 (the “’134 patent”). … THE PATENTS-IN-SUIT AND ENTRESTO® 178. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 179. The ’659 patent claims, inter alia…the ’331 patent, titled “Methods of treatment and pharmaceutical composition.” The ’331 patent was duly	External link to document
2019-10-17	3	ANDA Form	Date 8,101,659 January 14, 2023 8,796,331 …received) Date of Expiration of Patents: U.S. Patent No. Expiration Date… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: See Attached. Date of Expiration of Patent: See Attached. Stay Deadline: See Attached. (myr… ) SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG	External link to document
2019-10-17	4	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,101,659 ;8,796,331 ;8,877,938… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-03-14	402	Stipulation-General (See Motion List for Stipulation to Extend Time)	Regarding Defendant Alkem's Infingement of U.S. Patent Nos. 8,101,659 and 8,796,331 by Novartis Pharmaceuticals… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-03-16	404	Order	Defendant Alkem's Infringement of U.S. Patent Nos. 8,101,659 and 8,796,331. Signed by Judge Richard G… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-04-27	426	Stipulation to EXTEND Time	non-infringement position with respect to U.S. Patent Nos. 8,101,659 and 8,796,331, in accordance with the Court's…regarding the Teva infringement trial concerning U.S. Patent Nos. 8,877,938 and 9,388,134, and (2) Teva's deadline… 17 October 2019 1:19-cv-01979 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.